Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A van den Bogert

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|March 29, 2017
Generic drugs have lost their profitabilityCornelis A van den Bogert
BMJ (Clinical Research Ed.)|July 24, 2015
Need for a proactive and structured approach to risk analysis when designing phase I trialsCornelis A Van den Bogert, Adam F Cohen
Journal of Biomechanics|July 1, 1996
A method for inverse dynamic analysis using accelerometryA van den Bogert, L Read, B M Nigg
F1000Research|September 12, 2019
Causes of reporting bias: a theoretical frameworkJenny T van der Steen, Gerben Ter Riet, Cornelis A van den Bogert, et al.
British Journal of Clinical Pharmacology|October 5, 2017
Pharmacological vs. classical approaches in the design of first in man clinical drug trialsCornelis A van den Bogert, Adam F Cohen, Hubert G M Leufkens, et al.
Regenerative Medicine|February 28, 2020
Publication rates and reported results in a cohort of gene- and cell-based therapy trialsDelphi Gm Coppens, Helga Gardarsdottir, Cornelis A van den Bogert, et al.
Journal of Patient Safety|October 3, 2014
Screening Questions for Nonsteroidal Anti-inflammatory Drug Risk KnowledgeCornelis A van den Bogert, Michael J Miller, Daniel J Cobaugh, et al.
Nature Reviews. Drug Discovery|November 15, 2014
Regulatory watch: Outcomes of EMA marketing authorization applications: does partnering have an influence?Cornelis A van den Bogert, Patrick C Souverein, Michelle Putzeist, et al.
Current Medical Research and Opinion|March 25, 2016
Risk indicator taxonomy for supervision of clinical trials on medicinal productsPeter M J M Jongen, Cornelis A van den Bogert, Catharina W E van de Laar, et al.
Journal of Clinical Epidemiology|May 11, 2017
Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the NetherlandsCornelis A van den Bogert, Patrick C Souverein, Cecile T M Brekelmans, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|March 29, 2017
Generic drugs have lost their profitabilityCornelis A van den Bogert
BMJ (Clinical Research Ed.)|July 24, 2015
Need for a proactive and structured approach to risk analysis when designing phase I trialsCornelis A Van den Bogert, Adam F Cohen
Journal of Biomechanics|July 1, 1996
A method for inverse dynamic analysis using accelerometryA van den Bogert, L Read, B M Nigg
F1000Research|September 12, 2019
Causes of reporting bias: a theoretical frameworkJenny T van der Steen, Gerben Ter Riet, Cornelis A van den Bogert, et al.
British Journal of Clinical Pharmacology|October 5, 2017
Pharmacological vs. classical approaches in the design of first in man clinical drug trialsCornelis A van den Bogert, Adam F Cohen, Hubert G M Leufkens, et al.
Regenerative Medicine|February 28, 2020
Publication rates and reported results in a cohort of gene- and cell-based therapy trialsDelphi Gm Coppens, Helga Gardarsdottir, Cornelis A van den Bogert, et al.
Journal of Patient Safety|October 3, 2014
Screening Questions for Nonsteroidal Anti-inflammatory Drug Risk KnowledgeCornelis A van den Bogert, Michael J Miller, Daniel J Cobaugh, et al.
Nature Reviews. Drug Discovery|November 15, 2014
Regulatory watch: Outcomes of EMA marketing authorization applications: does partnering have an influence?Cornelis A van den Bogert, Patrick C Souverein, Michelle Putzeist, et al.
Current Medical Research and Opinion|March 25, 2016
Risk indicator taxonomy for supervision of clinical trials on medicinal productsPeter M J M Jongen, Cornelis A van den Bogert, Catharina W E van de Laar, et al.
Journal of Clinical Epidemiology|May 11, 2017
Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the NetherlandsCornelis A van den Bogert, Patrick C Souverein, Cecile T M Brekelmans, et al.
Pageof 2